MedPath

An Observational Study on Teriflunomide-exposed Pregnancies

Completed
Conditions
Multiple Sclerosis
Interventions
Registration Number
NCT03198351
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies.

Secondary Objective:

To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pattern of minor birth defects, spontaneous abortion, stillbirth, preterm delivery, small for gestational age at birth and at 1 year follow-up.

Detailed Description

The total study duration per participant is approximately up to 2 years.

* This is a prospective, observational study (no intervention), ie, patient registry.

* The statistical analysis for the cohort study describe baseline characteristics in all three cohorts, and then will compare pregnancy outcomes in cohort 1 to cohort 2 and secondarily to cohort 3.

* For the "registry" group, without comparisons, only descriptive statistics of pregnancy outcomes will be summarized.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
220
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Cohort ITeriflunomide (HMR1726)Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
Primary Outcome Measures
NameTimeMethod
Rate of major structural defects in live born infantsUp to the infant's first year birthday
Secondary Outcome Measures
NameTimeMethod
Proportion of major structural defects in all pregnanciesup to 1 year of age in infant
Rate of preterm deliverylive birth prior to 37 weeks gestation
Proportion of infants who are small for gestational age (less than or equal to the 10th percentile for gestational age and sex) on weight, length, or head circumferenceat birth
Specific pattern of 3 or more minor structural defects in live born infants receiving the examup to one year after birth
Rate of spontaneous abortiondate of conception to 20 weeks gestation
Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation1 year

Trial Locations

Locations (2)

University of California at San Diego-Site Number:001

🇺🇸

San Diego, California, United States

Investigational Site Number :002

🇨🇦

Canada, Canada

© Copyright 2025. All Rights Reserved by MedPath